Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here


Payment Information We Accept Visa, Mastercard, American Express and Discover


By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Tandem and Lannett Q3 ’22 Earnings Updates; Indigo Expands into US; OrsoBio Acquires T2DM and NASH Assets

Here is a brief preview of this blast: A series of cardiometabolic-related news items have been observed: Tandem (press release) and Lannett (press release) hosted their CY Q3 ’22 earnings calls; Indigo Diabetes announced the creation of a US entity and appointment of Peter Devlin as President to support the development and commercialization of its continuous multi-metabolite (CMM) device; and Orso Bio acquired a T2DM asset from Shionogi (press release) and exclusive global rights for intellectual property from Yale University to develop mitochondrial protonophores (press release). Below, FENIX provides highlights and insights for the respective new items.

About The Author

Matthew Maryniak

President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.